Post
The burden of hepatitis B and hepatitis C-related illnesses
Hepatitis B virus (HBV) and hepatitis C virus (HCV) are significant global health concerns, causing acute and chronic infections that …
High global prevalence of HPV in sexually active men
Human papillomavirus (HPV) is a highly common sexually transmitted infection (STI). The US Centers for Disease Control and Prevention (CDC) …
Could Gilead’s Trodelvy be the next TROP-2 therapy game-changer in NSCLC treatment?
At the recent IASLC 2023 World Conference on Lung Cancer (WCLC23), Gilead Sciences announced encouraging results from its Phase II …
New evidence shows depression as a major risk for type 2 diabetes
Depression is widely recognised as a mood disorder that may lead to a variety of emotional and physical problems. Depression …
Entrada Therapeutics doses first patient in DMD therapy trial
US-based biotechnology company Entrada Therapeutics has dosed the first subject in a Phase I clinical trial of ENTR-601-44 for the …
Signal: CMR Surgical Raises $165m to continue development of surgical robot
Cambridge, UK-based CMR Surgical has raised $165m in funding to continue the development of its Versius surgical robot. This latest …
Gilgamesh completes SAD and MAD studies of MDD therapy
Gilgamesh Pharma has completed the Phase I single ascending dose (SAD) and multiple ascending dose (MAD) trials of GM-1020 for …
NewAmsterdam Pharma reports data from trial of Alzheimer’s therapy
NewAmsterdam Pharma has reported initial data from a Phase IIa clinical trial of obicetrapib for the treatment of early Alzheimer’s …
Yale and Transcend wins US DoD grant for PTSD therapy
The US Department of Defense has awarded a collaborative grant to Transcend Therapeutics and Yale University (US). The grant is to …
Moleculin Biotech enrols all patients in trial of Annamycin
US-based pharmaceutical company Moleculin Biotech has finished enrolling patients in the second phase of its Phase IB/II MB107 clinical trial …
Medicenna to expand Phase III glioblastoma trial globally
Medicenna Therapeutics is approaching other regulatory agencies outside the US to expand its upcoming Phase III trial in recurrent glioblastoma …
Forxiga flunks primary endpoint in DICTATE-AHF trial
At this year’s European Society of Cardiology (ESC) Congress, research found that early initiation of Forxiga (dapagliflozin) failed to improve …
Can steatosis-associated fibrosis estimator scores improve diagnosis of NAFLD/NASH?
Non-alcoholic fatty liver disease (NAFLD), a result of excess fat buildup in the liver, is one of the most common …
Pain points: Unsolved recruitment and trial design issues in pain clinical trials
Pain is universal, yet it is highly individual and subjective. As such, clinical trials investigating pain face multiple challenges. Even …
Mendus shows early comparability data for its universal cancer vaccine
Mendus has announced that the immune response triggered by vididencel was comparable for patients with acute myeloid leukaemia (AML) and …